Transgene expression. (A) Vector dose-dependent systemic ova expression in BALB/c mice as a function of time after AAV-EF1α-ova administration. Mice were injected with varying doses of AAV-EF1α-ova at day 0 and were followed for 12 weeks (n = 5-6/dose). Mice received 2 × 10¹¹ (○), 1 × 10¹² (•) or 3 × 10¹² (▪) vector genomes (vg's)/animal. (B) Ova expression levels of DO11.10 transgenic BALB/c mice at the time point that they were killed. Mice received 3 × 10¹² vg's of AAV-EF1α-ova (▨) or 3 × 10¹² vg's of AAV-EF1α-GFP (▪). Note that none of the mice injected with AAV-EF1α-ova shown in panels A and B formed antibodies to ova. Error bars (A-B) represent SD. (C) Antibody formation to ova 2 weeks after subcutaneous administration of 25 μg ova in cFA is graphed for individual DO11.10 transgenic BALB/c mice that had been injected with AAV-EF1α-ova or AAV-EF1α-GFP 2 months earlier (3 × 10¹² vg's/animal). Shown are IgG1 responses (ova-transduced mice did not form IgG1 or IgG2a antiova after immunization). (D) Immunofluorescence staining of ova in a liver section from a nontransduced (top) or from an AAV-EF1α-ova–transduced DO11.10 mouse (bottom, 2 months after gene transfer). Original magnification, × 400.